-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IofmWAck1DJNUDz0cg2/ettTovAqCfx6XorIf2MG41QLDPhQY7aTi44bK+INt+L7
 tR526u5eN0mMZnQHl39LLw==

<SEC-DOCUMENT>0000950123-10-092318.txt : 20101008
<SEC-HEADER>0000950123-10-092318.hdr.sgml : 20101008
<ACCEPTANCE-DATETIME>20101008155818
ACCESSION NUMBER:		0000950123-10-092318
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101004
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101008
DATE AS OF CHANGE:		20101008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		101116186

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c06751e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): October 4, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, NJ<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#254;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;5.07 Submission of Matter to a Vote of Security Holders.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) held a special meeting (the &#147;<B>Meeting</B>&#148;) of the holders of its
6% Exchangeable Convertible Preferred Stock (the &#147;<B>Preferred Stock</B>&#148;) on October&nbsp;4, 2010, at 1:00 p.m. The Meeting was
called to elect two directors to the Company&#146;s board of directors.&nbsp; The Certificate of Designations governing the
Preferred Stock provides that, if the Company fails to pay dividends on its Preferred Stock for six quarterly periods,
the holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#146;s board of directors.
This right accrued to the Preferred Stockholders as of August&nbsp;2, 2010.


<P align="justify" style="font-size: 10pt; text-indent: 4%">The Meeting was adjourned because a quorum of the holders of our Preferred Stock was not present in person or
represented by proxy to transact business at the Meeting. The adjournment was approved by a vote of 324,678 shares of
Preferred Stock, with no shares voted against the adjournment, thus constituting approval by more than the majority of
the holders of the Preferred Stock represented in person or by proxy at the Meeting and entitled to vote on the
adjournment.


<P align="justify" style="font-size: 10pt; text-indent: 4%">The adjourned Meeting will be held on Monday, November&nbsp;1, 2010, at 1:00&nbsp;p.m. at the offices of Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., The Chrysler Center, 666 Third Avenue, New York, New York 10017, 25th floor.


<P align="justify" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On October&nbsp;6, 2010, the Company issued a press release announcing the adjournment of the Meeting described in Item
5.07 above to Monday, November&nbsp;1, 2010, at 1:00 p.m., and will be held at the offices of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., The Chrysler Center, 666 Third Avenue, New York, New York 10017, 25th floor. A copy of the
press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the information contained therein is
incorporated herein by reference.


<P align="justify" style="font-size: 10pt; text-indent: 4%">Neither the filing of the press release as an exhibit to this Report nor the inclusion in the press release of a
reference to our internet address shall, under any circumstances, be deemed to incorporate the information available at
our internet address into this Report. The information available at our internet address is not part of this Report or
any other report filed by us with the Securities and Exchange Commission.


<P align="justify" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Exhibit&nbsp;Number</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Description</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release, dated October&nbsp;6, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="center" style="font-size: 10pt">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top" colspan="3"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" colspan="4">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Paul McBarron</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:<BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul McBarron<BR>
Executive Vice President&#151;Finance,<BR>
Chief Financial Officer and<BR>
Chief Operating Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="justify" style="font-size: 10pt">Date: October&nbsp;6, 2010


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c06751exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">


<P align="right" style="font-size: 10pt"><B>Exhibit 99.1</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><IMG src="c06751p0669301.jpg" alt="(LOGO)"></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="middle">Cyclacel Pharmaceuticals, Inc.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">PRESS RELEASE

<P align="center" style="font-size: 10pt">CYCLACEL ANNOUNCES ADJOURNMENT OF SPECIAL PREFERRED STOCKHOLDERS MEETING



<P align="left" style="font-size: 10pt">BERKELEY HEIGHTS, NJ &#150; October&nbsp;6, 2010 &#150; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a
biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the
treatment of cancer and other serious diseases, announced today that a special meeting (the &#147;Meeting&#148;) of the Preferred
Stockholders (the &#147;Preferred Stockholders&#148; ) of Cyclacel Pharmaceuticals, Inc., was adjourned&nbsp; until November&nbsp;1, 2010,
at 1:00 p.m. (Eastern Daylight Time), and will be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C., The Chrysler Center, 666 Third Avenue, New York, New York 10017, 25th floor. The Meeting was adjourned because a
quorum of our Preferred Stockholders was not present in person or represented by proxy to transact business at the
Meeting.


<P align="left" style="font-size: 10pt">The Meeting was called to elect two directors to the Company&#146;s board of directors.&nbsp; The Certificate of Designations
governing the preferred stock provides that, if the Company fails to pay dividends on its Preferred Stock for six
quarterly periods, the Preferred Stockholders are entitled to nominate and elect two directors to the Company&#146;s board
of directors. This right accrued to the Preferred Stockholders as of August&nbsp;2, 2010. The adjournment was approved by
the vote of the majority of the holders of our preferred stock present in person or represented by proxy at the Meeting
and entitled to vote on the adjournment.


<P align="left" style="font-size: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control
for the treatment of cancer and other serious disorders. Three product candidates are in clinical development.
Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, will be entering Phase 3 development for the
treatment of Acute Myeloid Leukemia in the elderly under a Special Protocol Assessment agreement with the U.S. Food and
Drug Administration, and is in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or
R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and
nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2
inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary markets
directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia.
Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug candidates. Please visit
<U>www.cyclacel.com</U> for additional information.




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt">2


<P align="left" style="font-size: 10pt"><B>Forward-looking Statements</B>


<P align="left" style="font-size: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any future results expressed or implied by
such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the
efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148;
&#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be
uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces,
please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed
with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>. Such forward-looking statements
are current only as of the date they are made, and we assume no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.


<P align="left" style="font-size: 10pt"><B>Contact for Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Investors/Media:
<BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>


<P align="left" style="font-size: 10pt">&#169; Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks
of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c06751p0669301.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c06751p0669301.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%4`V`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@#(UO7]#\-6,FI^(=8TS0].A_UE[JM];:?:J<9P
M9KF1%W8Z*#D]A73A,%B\=6CA\%A:N+KRVIT:<JD__`8)NWGL<F-Q^!RRA+%9
MAC*.!PT-ZE>K"E!?]O3<5?RW/GC7?VP/@7HCR10>)+[7Y8N"GA_1;^[C9@Q5
MECN[J.VM6(QG(GVD$%2<U]M@_#+B[%*,I8&G@HOKB*].#6E[N$'4J*_^"Z>Z
M1^>8_P`7^!<"Y1IYE5Q\X=,)AJLTW>UE.HJ5)][J=FK--W.-3]NGX0F14;0?
MB'$A;!E?1_#QC4?WV6+Q6\FWV5">>E>H_"+B9)M8S+6U]E5\2GZ:X11^]I>9
MXL?'3A#F47@,V@KVYGA\)9>=HXYRMZ1;\CTGPY^U3\#/$DJ6T/C6#1[F1E1(
M?$=C?Z&I9D+$?:[RW6U&,;<FX`+8"DY&?"QWAWQ=@(N<LJEB:<;MRPU2G7TO
M;X(2=37?X+VU=CZ7+O%3@;,9QIPSJ.#J2LE'%TZN&5VK_P`2I%4E;;6HE?17
MNCW^UN[6^MX;NQN;>\M)T$D%U:S1W%O-&<@/#-"S)(A(/*L1Q7QE2G4HSE2J
MTY4JD':4)Q<91?9Q:33\FC[^E5I5Z<*U"K"M2FKPG"2G"2[QE%N+7FF6*@T"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^*OCY^UMI7@":\
M\)?#];+7_%\!EM]2U.8F70O#4Z_*T+B-A_:FJH<DP(ZQ0E0)G9@T-?JO!OAM
MB,YA2S+.7/!99*TJ5*/NXC$Q>JDK_P`*B^DVG.:^"*5IGXKQ]XM87A^=;*<@
M5/'YO#FA6K2UPV#DM'%VM[>O%[P34*;_`(DI24J9\6Z+\,_C[^T5J`\27B:I
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MQ^-WC6PN&(07>I^";JXL8WSS)(D6DVI6(CI^]&.N379'-O$2G>=7A/`UH+7D
MI8Z$*C79-UJBO_V[\C@ED?A54M3H<;9CAZCT52MELYTD^K:C0I-1_P"W].[*
M\_[-LNO0SW7PE^)/@;XH1Q>:RZ/:WZ:!XH:&,9W#1]1E978XDZS1@[,+N)XN
M''4<%*%/B3(<?P\Y67MI4WB,(I/I[:DDUTVC)J^MC.IX;3QT)U.$N),LXG4.
M9_5X55A<=RKK]7K.VNN\XIV]V]SA?"WCWXM?`7Q%)8V-QK/AB]M9`VH^$]>M
M[C^RKQ,D'[3I%R1&T;KD+=VAC?!#1S=*]?,,FX;XPP4:M6%#'TJBM2QF'E'V
MT'_=K0O)-=:=1-=)0/#RO/\`BW@+,94*%3$996I2O6P.*A/V%1;>_AYVBU+[
M-6DXRMK"H?J5\"/VB?#?QGM9=/-L=`\9Z;:)<ZIH$DGFP7%N&6*34=&NB%-U
M8B9T#QN%EA,J*X92LC_SWQ?P1CN%:D:W/];RJO-QI8A+EE&5G)4J\->2IRIM
M23<)I-Q::<5_4G`GB)EO&=*>']G]0SG#04ZV%;O&4+J+K8>>G/3YFE*+2G3<
MDI<R:G+Z+KX@_10H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#XK_
M`&MOCW/X`TE/A_X2NVA\8>(K,RZCJ%M(PN/#FASL8E>W*#*:M?L)8H"#NBC2
M24#>T)K]4\-N#H9SB7G.94^;+,#.U.G)>[B:\=6I7T=&CI*ITG)Q@WRJ:/Q;
MQ:X]GP_A(\/Y35<,XS&G>K5@[3PF&D^5.-M57KZQIM>]""E-)2=-GB_PR^!'
M@SX6^$8_C+^T"5VQI'>:'X*ND\]C<W`,MBFI64A!U;7[@J9$L&)AA!+W.XH_
MD?59_P`89IQ!F3X6X+3NVX5\=!\ON1]VHZ51:4</"]I5DN>>D:5DX\_QG#/`
M>3<+93'C+C^UHI5,-ETUS>_-<U-5J3LZ^*J?%'#M^SIJ\JUVI>SQ=1\8?'S]
MJ2^O--\$6DO@SX:V3O:R+%>-H^@VEI",A=?UV%%EU:[6W$9>QLU,,8`_=``R
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MOPWJ8AD!_=LUB`#*#SP2,5U<GB12Y9\^18E)KFI<F*I<RZI5.GK;4X?:>$M7
MFIJEQ)@VT^6KSX*KROHW3TNGVNAZ?!#2/$V=3^!OQ-TOQGJ-FGVM/"NJ+)X,
M^(-L8U>1AIT%U(D.IS1*@S);2P!B<)GC<GQ9B<O_`-GXMR"KE5"H^1XNDUC<
MNE>R_>2@G*DI-[3C-I?%;6U1X(PF97Q7`O$U'.,117M%@:REEV:PLG)JC&;4
M*\H)*\J<X)OX;Z7W/#WQ3;Q)<P?"3]HO1;[7;1;^+1-/\37ELUG\1?`>JW,J
MVT#O>/$+C4+,3RIYL5PKNRX9OM"*L9Y,;P\L!3GQ)P/BJ>"J>S=>IA824\LS
M"E%<TDH)\E.;BGR2@U%/1>SDW([LNXI>95(<(^(N"JXZDJD<-2QE2#IYOE=:
M348MU&O:5::DTYPJ*4FM7[5*,#K_`(LVFA?\$ZO`6M_'V674/BEX@O+ZV\`^
M#/#[0Q>&=,@O/$0N;YKS7;Z&2_DECBL]$F=C!%'O:,1(B&?S;?\`*.+/$+$<
M3Y=1RU9=#`48U(5:K55U93J0C)14+PA[."YI.SYY/3WE9W_;>!_"S"\&YKB,
MV>:U,QKRI3H4(NC&A&E3J2C*3G:I4=2HU"*37)%>\^5MKE]U_82_;''[8?P^
M\2:]J'A!?!GBGP3K-IHOB&QLKU]0T.]_M*UEO=.U'2)[A$N($>."XCEM9Q(T
M30@B:591L_.3]6/N6@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`RM=U
MFQ\.:)J^OZE)Y.GZ)IM[JM[)D#9:V%M)=3D;B!N\N)L9(YQ71@\+5QN+PV"P
M\>:MBJM.E37]^I)0CMYLY,=C*&78+%X_$RY,/@J-6O4?:%*#G+RO:+MYGYM?
MLW>#;KXV?%+Q5\=/'4"SZ5I6LR7>G6MT-UI-KS(LFGVX$N5:PT+2A:84G`F:
MV)SY;@_NO'6:4^$^'LNX0R>3AB,104*DX:3CA[M5)::JIC*O/=K7D]HM.:)_
M-WAODU7C7BG->.<]@IX7"8AU*,)ZTY8JRE2CKHZ6!H<ED_MND]5&2+5[;W?[
M67Q=UG4-3U&XTSX&_"][B.2[2X^RV]Y%;^8]Q/%*Q"Q7NIK;R32W6,VNGPQ`
M%9)%+YTIT_#?AK"T</0C7XMS]1:@X\TH.5E&+BM7##N2C&GM5Q+D]8IVVK4Z
MOBQQ=C<1B<3/"\#<+N2<U+DA4C"[E*,F[*IBE!SG5M>CA8Q6DW'FFO)O$'Q_
MCOM!\%7=I\(_V8/`YDL+W6UC32K?7(+!`UQ(8F>(72$$2"WE=((EE26\:6YD
M6(32A@N"W1QF:4I\2<?YM:I3H7=66'E4?NJZ4N1_9<XIU)M.%%0I)R*K3S#C
MZ-?`9+6I\(^&&1WI5,394(8F%))S;BW!33^)4YR5."DJF(<ZTE`RO"\/@5)7
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MH>RQ56K%J_\`R[IMK=6/%8O!'PR^*&HO8_#B/6/@M\8=-F>6V^'WB:_N4TG5
M-0MOWHMO#FN3B.\T;5E*,R12A#D*%AVAIA]7+-L_X>H*KGCH\4\,5XI2S'"T
MX.M1IS]WFQ-"-Z5:B[VE*-U:]YW:@_BX9)PQQ/B70X<CB."N,,-)RAE6,JS5
M"O5A[W)A,3+EK8>NK7C":B[I)0Y5*HOI?0]9\(>&T\!>'OV@]6^%MM^U)JL&
MI1_"^R\57^DOXEUB2)Y;/P@=1N+.0QW]V^IP"&*9G9I)%VP,UWY@K\>XCS[#
MX?&X_`\(YAB<-P]C8Q=3#QE4IT'4FG[94J<[3ITI-V<4HIZQLX<J/WGA/AG$
MXC+\LS'C?*\+BN*,OE)4\3.-*KB(TH->P=:K3O"K6A9RC-N;C[LKJHY,^=/V
M3_`O[6GQN/QN^'W[?O@M?$WPIOY+-M&TSQCINB6,@\6VNKFX+^"KCPV8)QX>
MM[)6>._AE*JXM5M+@[[I3\,?HQ^D'P?^"/PL^`?A7_A"_A-X/T[P?H#73:A=
MP6;75S=ZEJ+PPV\FH:KJ5_//=ZC>-#!$GF3S/M6-40*BA0`>K4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`R21(D>65TCCC1I)))&")&B`L[N[$!$50222`
M`,F@"E9:MIFHEAI^H6=X5A@N"+:XBF(MKKS/LMT!&Q)M9_*E,4PRD@C8HS!3
M@`^<OVO]?;0?@3XGCBD$<VO7>C^'X_F=7=+R_CN;R.(H1\YT^RN\@\%0P(.:
M^^\,\$L9Q?E[<;QP<*V(>UDX4W&#=^BJ3AMK>UC\R\7\>\!P+F<8R49X^>'P
ML=TVJE53J15K:NE3J7OHXW3N<%JL;_!3]C4Q6`-KK&H^%+-9YHE,<_\`;/CN
M>`7LS;U5Q/!!J<D8XWHMH@!_=@U[.':XJ\4;UO?PM#%S<8O6/L,!&7LXJUUR
MSE23?23FV_B/!Q4'P5X-\E!.CB\3@::E*/NS^L9I.*J2=TGSTX5G%.W-%4XV
M^%'*>(?!U_X+^!OPB^`WALFR\3?&35[6'Q+?0H?,CM)H+?6O%MQ*T8.]+:VD
MLK,_,`]M;,OW20/1P69T<TXMXEXPQR]K@.%Z,Y86FWHYQE*A@XI.UG4DJE5:
M:59)[V/*Q^35\EX(X2X#RY^PS+C&O!8RI'XE"488C'2;5^94HRI47JN:A3DM
MKFWXQT+PSJNH7/PVDEGT'X`?L_:#IVJ>.X+,M%+XL\326PU#3?#DLL.Q[S%L
MZ75P(_GFNM0"<2R0O'R97B\?AJ-//8QCB^,N,\15I9?*=G'!X52]G5Q*3NH>
M\G3IW]V%&G?6$9QEW9Q@<LQ%>IPY*<L!P#P!A:5?,XT[QECL8X>UI864H\KJ
M/E:JU>5\U2O4:LJDJ4X]YH?PH\4?$S3;._\`B%J>L>`?!9MU'A?X.>"+P^&[
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M-\`1%^./O#[;H`*`/C[XH?MX_LO?";Q)-X*UWXBIKOC2VN!:7/A/P'HNM>.-
M9M;LJY-G=CPY8W-M:7RLFQ[6:YCGC:1!)&NX&@"KHO[>O[-_B#P)X_\`B!H_
MB'Q1=Z5\*QI$OQ$TK_A`_%MOXE\)6FN7D]AI^H:GH5UI44[6#7%M/YDUMYX@
M2,R3^7'\U`'U!X&\;^&/B1X/\-^//!>JPZWX5\5Z3::WH6J6ZR(EU87L8DC+
MPRJLEM<(VZ*6"5$EAEBDBD57C90`>>S_`+0?PRB^-]M^SQ;ZIJ&I?%*7PZ?%
M5[HVE:1?7UEH.A^6\JW?B'6(8C9Z.SQ_9BD5Q*LC_P!HV6U3]KBW@'-?&O\`
M:Z_9Y_9[N8],^*/Q(TK1O$,\4,UMX3TZWO\`Q#XJFBN,?9Y&T'0;6[NK.&96
MW1RW:6\<@!V.QP"`<_\`![]M?X!?&[QG'\.O!^M^);'QS/IUQJ]GX9\6>"/%
M7A:_OM,M(7N+F^M)-4TM+62".W42<W"LRR+M#$D``]/^%_QX^&_Q@U_XF>&?
M`NJ7M_JWPB\4MX.\;PW>E7VFQV&NK+J$#06D]Y"B:A#YNEWJ^=`73]T#G#*2
M`>QT`?.7[0/[5OP2_9AB\+2?%_Q-<Z"WC&?48=!M[#1M4URZN%TA;-M1NI;?
M2K:9[:TA.H6:F60*&:<*FXJVT`]_TS4K#6=-T_5]+NHKW3-5L;34M.O8#N@N
M["^@CNK.ZA8@;HI;>6.13@9#B@#@OBG\8_A?\$O#O_"5_%;QOH7@C06F-O;W
M>LW++-?W03S#::7IUM'+>:M>"/+F"RMYY`H+%<#-`'R;8?\`!3/]D>]N[))?
M&'BS2M'U*]_L_3?%FK?#;QU9>%+^Z.\+';:N=#8'<5&"\:#]XI.!N*@'J/QU
M_;0^`O[.7BS1O!'Q1U[7=-\1Z]H:^(=,L='\)Z_XA\_2VO+VP$IDT>RG5)/M
M&GW8,9^8+%N(P02`9/P@_;H_9[^.7CK3OAS\/M8\67?B?5+34KVT@U7P'XJT
M&R,&DV<E]>&34=4TV&WB86\3E59P7;"KEF`(!ZIX%_:&^%_Q&^)_Q)^#_A75
MK^[\<_":2"/QII]QH^H65I8M<3?9X_LFHW$*V^H#S?E/D.V.O2@#TGQAH<WB
M3PUJVB6UQ';3WT"+$\ZNUL[PSQ7(MKQ(R&>QN/)^SSJN289Y!M;.T@'C'P<^
M#NM_#[6KG5M5U[4-45].U:U"ZG??;KPSZW<^&YY+"%X52%/#ND'PV_\`9>]?
MM17Q'?+<!#&IF`//?VY83/\`"CPS'A]C?$S04E9!_JXYM!\50%SV'SRH!GC<
MRCO7ZEX224.(\P>B:RO$-)Z7:Q&$E;[DWIT3/QCQR@Y\*99&SY7G.%4FOLJ6
M%QT;_?)+7JT;'[6=HTGPG\(VD9$=K_PL3P%!=LP`A2S=[F#=.HP/)$SP9'`S
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M"U.JK)#I]S!,;EM*%ZMNPD"I<-`\BO&KHX!D>$/!6E>"[75+33;O7=035?$W
MB'Q7--XBUS4?$%U:ZAXEOY=0OK33KK5)Y9+#1XI)FCMK&%EAMX0(XU"]0#KZ
M`"@#X9_X*-?%[Q-\&/V3_'_B'P;<W&G>)M?N-&\#Z7K%K,;>ZT0>*+T6FHZG
M:RH0\5ZFDQW\<$L;(\,]Q#,IS#R`=[^R-^S;X"_9U^#_`(0T+P_H.FIXMU+0
MM*U;QUXL>W@N->\1^)]0LX;S5)KO5F5II+""[FEAM+99/*AAC3:N]Y))`#Z-
MU7PSX>UNSUFPU;1=,O[3Q#I-SH6N0W-G`_\`:NC7D4\%SIE^^P/<64D5U<J8
MG8K^_?`!8F@#\8/`_P`91_P3-\2?&[]GWXDMJ6L?#$:-K/Q;_9;NW2ZN)-;;
M4[LP3_#$W:1-Y-ZVL31>;(VU(I+34+UQC5(%8`]^^`?@+Q5^S7^SE\=OVL/B
MM:-K'[1/Q(\)^*_C+XZ%U"J3:+#IVBZAK?A;P#!#(1]AM+&,0FYM0RB*67[(
M"T6G0$`#?^":7P1T2/X067[2GCJTM_%OQN^.>H>(/&.O>-]=B@U+6+/2[O6K
M^TT_3=*NIT8Z;;W%M:B\G6W$1=[T0/F&T@2,`_362QLI;FWO9;.UDO+3S/LM
MW);Q/<VOFQM%+]GG9"\.^)W1MC+N5B#D$B@#\M?^"=O_`"6K_@H+_P!G%S_^
MG3QQ0!^JE`'X[Z;\/=&_;M_:B_:F\2>(4AOOA;\)_A]J_P"S1\-[QU%S:1>-
M];MKY?%GB[3`?E:_TR_:],<\6P-%?:<59Q&20#WG_@FG\2]9\3?`6Z^$_C1F
MB^(W[.'BK5O@_P"*K*;>+B*RT*XFC\-3GS`&-NEA%/I<;LJ,Q\/R,5YW,`>`
M?`7PYHG[7O[<7[2OQ4^*45OXO\,_LXZ]8?#/X3^!];M?M?A[19S?ZW9S>(3I
M%Y&T$U]]I\+:A=YF1\W.L"7G[%:>0`?K_=:7IE]9/IM[IUA>:=(ACDT^ZL[>
MXLGC((*/:RQM$R$,PVE<<GUH`_&?]KWXK>`_@E_P4F_9Q^(_Q*U.31O!VA?!
M?Q!'J>H1:9>ZN\#ZG)\0],L0+#3[>:>0/?7=NA:.-M@?>>%)H`^[O@A^VQ^S
M3^T%XSE\"?";QA<:[XI@T6^U][*;PGXBT15TJPGL[:\G6\U72K>$LLM_:CRQ
M)O829"D*<`'QY^QO_P`I$?V^_P#K\T?_`-.S4`?KY0`4`?.G[5WAZ?Q#\"O&
MB6J,]UHL5AXD@6-`TFW1+^WN[QD)8>7MT\7;%AR%#8!S7V_AUC88'B[*G4:C
M3Q3J8:5W97KTY0A?O>IR))Z7L?G?BKET\PX&SF-)7J8)4L7&RNTL/5C.HUJK
M<M'VC;6MD]'<9\2[1_BE^SA<ZAH2+<7U[X1T+QGHT,3^:'U+15L/$4-HI129
MG,UE);[``78[>,T\AJ+A[CFG0Q;]G2HXS$8*LVN6U*NZF&<];<JM-3OT6NHN
M)*3XG\.:F(P*YZU;`8;,*$8OF?M<.J6+5-:>])NG*G;[4M-+C?$_B*VU'2O@
MK\<["7?H^ESV[>()8R%CMO"OQ!TNWTK5;JY52^R/3-:&C7,XR?*2PG+$*CL'
ME^!J8?$<5<(U8\N)Q$9+#1>\L7EU65:C"+TUQ%#V\*>W.ZD+)MQ1.:9A3Q&%
MX*XYH2OA,)*/UMK10P.:T84*\YI7LL+B?J]6JM>2-*I=I*36M/HATWQ#XF\)
M0M!93>(M:B^*/P\O)L1VC^)K)K2?Q)HTC)M+NU_:K?2H/,>6T\17K("+5Q'S
M0Q2K8+`9C)2J1P-!Y3F4(ZS6%GSQPM=)W22IS]E!^[&-;#4E*SJ1YNN>!>&S
M#,\I@XT)YCB8YWE-26E-XVFZ<\9AVU9MNK!5ZD?>E.AC*\HW5*7+[!HFMVVM
M6S/&K6M[:LL&J:7.0+W2KW;F2UNH^.^3'*H,<R;98F>-U8_,XO"5,)446U.E
M.\J56/\`#JPOI.#_`/2HOWH2O":4DT?7X'&TL;2<HITJ]*T:]"6E2A4MK3FO
MQC->Y4C:=-R@TS:KE.TKV]U:W0D:UN(+E8)I+>5H)4E6.XB($L#F-B%E0D!D
M/*G@@&KG3J4G%5(2IN45**DG&\9;22=M'T>SZ&=.K2JJ3I5(U%"3A)QDI*,X
M_%%V;M)/1K=/1EBH-`H`^2_VWO@%J?[2/[./CCX:^'IHX/%A_L[Q)X0%Q<+:
MVESXB\.W:7UKIMW,_P`D4-_;"\LA*Y5(I+R*9SMA.0#YU_9L_P""@WPK@\$Z
M)\-?VD=9E^!OQN^'NG:?X2\8Z'\1K/4=$MM6O-'A73$\0:?JUW`8/+O4M5GF
MBNI87CFDEV>=;^7<3`'VU\+?VA/@O\:[_P`1:9\)_B)X>\>77A.+3)O$'_"/
MSS75OIT>L27\>FLUX8%@N!,^F7V/(DEV^3\VW>FX`_/?_@IK;6DWQ(_8/^T6
M]M-N_:)T^W;SX8I-UO-J_@LRV[>8IS!(Z1;HS\K%4W`X%`'Z9_$[P+I_Q/\`
MASX[^'&K2R6^F^.O"/B'PE>W$.1+;6^OZ5=:9)<1A64EXA<^8`&7)3&1F@#\
MF_V0?VG=,_9$T*3]D3]KH7GPN\0?#K5-:B^'_CO5K34;CP3XV\(ZAJ=[JT$E
MCK=M:RI%'!<7D_V>=\0-;W%O;2&"[M986`/T9\#?M6_LZ?$SQC8>`/AY\6_"
M/C3Q;J5G>ZA::/X;NYM4<V6G6IO+VXENK6W:UMUB@P2LLZ/N.T*6!``/S0_8
MZ^/_`,%O@Q\<OV[K3XJ?$KPIX#NM>_:%U*XT:#Q%J26,FHP6&L>,HKR6U5E/
MF)%+<0JY'0R`'K0!]H?'?]L_X5>'_P!F#XM?&3X4>/\`PYXTG\/VLG@[P]>>
M'[X7L,7Q$\16T-KX>LVV*#)-:MJ,&J2Q+S]FLIFRH!*@'S#^S=^Q+^UA\./A
M%X7L?"G[8MS\+4\3VL'CKQ!X,@^"?A'Q1)I'BCQ58V5[J]M>>(=9UO[7JM]"
M5@MI9G5%+VA$:B,+D`XSX>>'OB)^Q?\`M]^&[7XI?$P?$_0_VP_#MQI.K>.6
M\)Z?X'MYOB3HUVD>BPW.A:5>SV<-\D@TVR2>%U\__A,G9XA(CRD`UY?$&I?\
M$]/VN_C#XS\=>'M:F_9>_:8U*S\3-X^T'1IM3M/`7CA9]1O6LM<MM.B>:&!;
M_5M=C\M4+S6U]93VZSR6MS$H!]QR_MZ_L=Q64-\/V@OA]-'<.(X;:UU"YNM2
M:1BJJC:3;V;WL)9F`!D@09/7@X`/B?\`:C\:>`_A]_P4W_9L\5?$K7="\-^#
M]-^"OB1=4U;Q(8ETBV:\_P"%C6=DMR98I$5I;V:"*,LO^L=.0>0`?H!\.?VD
M_P!EOQ_XKL?"7PP^)_PU\0^,-3@O6L-'\-75DVJW=O96TE_?>2D$",\<5K;2
M3.,_=A+8^6@#\Q_@)\:/A1\&/^"@?[<^H_%3Q]X;\!V.M:MIUEI-SXBOEL8M
M0N[74?/N8+5V4AY(XG1F7@@.#ZX`/UM^&'Q[^#/QHFUFW^%/Q(\+>/)_#T5C
M-K<7AS44OGTR+4FNDL)+L*H\M9WLKL(>Y@?TH`]=H`JWUE:ZC97FG7L*SV5_
M:W%E=P/G9-;743P3Q-C!VO$[*<>M:4:M3#U:5:E)PJT)QG"2WC*#4HM>C29E
M7H4L31K8:M!5*->$J=2#VE"<7&47Y.+:/FS]GN[N/!TWBSX#:_,[:I\/;^>]
M\+2W&`VM?#S6KA[G1[V`XQ+]DGFEM)@"1&S11\;<#[KC2E#,HY=QA@X*.'SJ
MG&&+4=J&94(J%:G+M[2,54@].=*4NNOYQX?UJF3SS7@7'S<L5D%653!2GOB<
MJQ,W.A4B_M>RG)TZB5U!RA#[+2M^&[.Q^&_B75_@_P"([>&3X=^/[G6-0^'4
MUX,Z;'+K/G7'B;X:71?"12++-=7NG1,1Y]M=3PH6DMMM9XZK5SO`8;B;`SE'
M.\EC1IYE&&E5JC:.%S2%M6FHPI8F2_AU80FTHSN:Y;1H\.9EB^$,QIQEP[GT
MJ]7*)5%^Y3Q'-+&9/4O:,6I2G6PD7_%I3J4TW.G8T)((/"%G;>`/B#<W7_")
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MR;#38B7EE`-Q.2(ZPG1HXRI]4R^GB<WS+$23>(DIQVU:I45*4FOYZU>22BOX
M=/XCIIUZ^74OKN9U<)D.482#4<+"4);Z1=:NXPA&5_X=##0;E-ZU:MU`[C2]
M1AU;3K/4[>*[@M[Z".Y@BO[2>PO%BE&Z,W%E=(DUK(4(;RY41UW`,H.0/)Q%
M"6%KU</.4)3HR<9.G.-2%UH^6<&XR5].:+<7T;6I[F%Q$,7AZ.)IPJ4Z=>*G
M&-6G*E449:KFIS49P;6O+)*2OJD]"_6)N%`'$>+_`(:?#GQ_&L/CSP#X+\:1
M(JHD?BSPOHGB%452Q54&K6,^Q07?`&,;V]3D`N>%/`?@?P'9OI_@?P;X5\&V
M#[!)9>%O#^D^'[63RP1'YD&DVD"/M!.-RG&3CK0`>)?`G@GQE<Z%>>+O"'AG
MQ1=^%]176/#5SX@T/3-8N/#^K(\,B:GHLVH6TK:9?J]O`PN+<QR`PQG=E!@`
MZN@#GO$?A+PIXQL3I?B[PSX?\4Z:0X.G^(]&T[6[(B387!M=2MIHOF,<9/R\
M[%_NC`!S_@_X2_"OX>2O/X!^&O@'P1/(C1R3^$_!_A_P[/)&[%GCDFTC3[=W
M0LS$J6())XYH`Y/5OV:OV=M=U/4-:UOX$_"#5]8U6\N-0U/5=3^''A"^U'4;
M^\E:>[O;Z\N=(>6ZNYIG>2261V=V<LQ))-`&E:_`+X&66@CPM9_!SX7VGAH:
M];>*1X>M_`?AB#1/^$EL[5K*T\0?V7'I@MO[:ALW:".]\OSDC8HKA3B@#UN@
M#D?%/P_\"^-Y=$G\9^#?"_BN?PU?C5?#L_B+0=,UF;0=3#0N-1T:74+:5],O
MM]O;MY]N8WS!&=V4&`#I;RRL]1M9K'4+2VOK*Y3R[BSO((KJUGC)!*36\Z-'
M*F0#M92.!0!Y=IWP#^!FC:L=>TGX,?"G2]<+B3^V-/\`A[X2L]3$B@@.+ZWT
MA)E<`D;@X/)]:`+_`(U^#'PA^(^H6VK?$+X7?#WQSJEE9C3[/4?%W@[P_P"(
MKZUL%FEN%LK>ZU;3YY8;43SS2")&"[Y7;&6)(!0\*?`/X&^!-;MO$G@GX.?"
M_P`(>(;)+B.SUWPUX$\,:'J]K'=P/;726^HZ;ID-Q"DUO+)$X20!TD96R&((
M!3U[]G/]G_Q3K&H>(/$WP0^$WB'7M6N&O-4UK6_A[X3U35=1NW`#W-]J%[I,
MD]U.P509)79C@<\4`=)X'^$OPL^&4FHR_#CX<>!?`4NL):QZM)X.\*:'X:DU
M..R:=K-+]]'L;<W:0-=7)C$I8(;B0KC>V0#T*@`H`\2^+GP]UG6YM#\?^`I8
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M"I!JECL#5;AB\!BX/9VY:E.I2J1<J&(AR\W*IP::E%9BZKXQ^'UM)H?Q`TV^
M^(_@?R?LL'C;2]+_`+5UVWL"I1K;Q[X5M8GEU'9",/JNEP7"S*-UQ:0NS,_0
M\-EF<U(XO):]/(LV3YY8&K5]CAY5+WYLOQ<VHTKRUCA\1.#@]*=::22Y%BLX
MX?I2P.?X>KQ'DG+R1S&A0]OB84K6<,TP-.,I5N6.DL5A:=15%[U6A"3;=WPQ
MI?@S6(!=_"KXB7>EV:AR=(T#5]/UG1;1Y?.`C?PUKMO>_P!B%9-Y^S6RZ>`8
M\;!CC+'U\TPD_9<0Y)"O5T_?8BC4H5YI<NJQ6'E2]O=6]^HZU[WYG<VRS"Y-
MC(>UX5XBJ86BD_\`9\)B*.(PU-RYM'@\3"M]6M*_[NDL/9JW*K'2#PQX^9U%
MQ\3IDME4AQ8^$/#]K=N"'R[7-V;N)'^9<%;90-@^7))/!]?R9)^SX?CSMZ>T
MQN(E!;:<L/92:WWFWKOL>E_9>?MI5.)Y1II:^RR_"PJ/>[YZGMH)ZK54TE;;
M=G#W]Y\)/`NK6UYXD\2W7C+QQ;,1IEMJ5]<>,_%RW0CCPNA^%=)A>/2;A\@^
M99:;9@><[/(J%B/6HTN),VPU2E@<!#*LIFOWLJ5..!P?)=ZU\76:E6BOY:M>
MJW9)1<K(\/$5N$LBQ=*MF693SC/*;_<0K599CCU.RTPV!H1E&A.6_-1PU%+F
MDY34>9KK_#E_\1/$VLV^MZCIZ>!?!ULD_P!D\-ZA%:W_`(O\0F:(I!=Z[)%)
M);>&+6(E98[&VDN+IF&+B6$`PGS<=1R3+\+/"4*SS;-)N//B:;G3P>&Y7>4,
M.FHSQ4Y:QE6G&%)+^'";:FO8RZOQ#F6,IXW$8=9%D])2]G@ZL85<?B^:+4:F
M):<J>"A!M2C0IRJ5Y2_BSIJ]-^G@C)`(R,9`/(SR,CM7SY]/IMV%H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/'_'/PFAU_6(?&W@_6;CP)
M\1[&W%O!XETZ".>SUFT1@Z:1XNT=RL.O:664`>85GAX:*4;`I^FRCB.6"PTL
MIS/"QS;(ZLN:6%J2<9T)O1UL'65Y8>KK=\MZ<]5.+NV?(YYPI#'8N&=91C)Y
M%Q%0CRQQE&*E3Q$%M0QV'=H8JB[)+FM4A9.$_=43GX/C#K?@PBP^-'A"]\+^
M3B,>.O#5O?>(_A]J.-P%S+<VD#W_`(::0#=Y&I6X51N_?D#-=L^&,)F?[[A7
M,Z>/YM?[/Q4J>%S&E_=4)RC1Q7+MST)W>G[M-GG0XPQN3?N.,\HJY7R:?VG@
MX5,7E57^^YTXRKX/FW5/$T[))MU+(ZI-(^#/Q/9-7M;;P+XON/\`7KJNFOI5
MYJ*L`8!*U_I[_:HW4(4!:0%=N!C%><\3Q3P\GA9U,?E=->[[&JJM.E_-;V=1
M>S:=[M*+3OK<]2.$X,XG:QE*EEF;U/B5>BZ%2LG;EYG5I/VL6K63<DU;2P[_
M`(4K\-3Q-X?N+J+D-;7WB+Q/?V<BD$%9K*]UJ6"9,$_*\;#VI?ZU9ZOAQD:4
MNDJ>&PE.:\XSIT(SB_-23'_J5PUM++YU(]85<7C:M-I])4ZF)E3DO*46C/G\
M2_`SX/V[P#4?`?@P@>0UCIB:;!JMQY3X$(T[2XWO[V17EX012,-QXK>&`XNX
MEFI>PS#-/M*I5=5T8W7Q>TJM4:::6_-%,PGF7`W!]-P6(RO)=.5TJ*HQKRY7
M\/L:"E7J-.6W))J^QSC^/_B7\1Q]D^%GA2Z\'Z'-A9?B/\1=.DL=L+#)F\,>
M"I66^U:8K_JY]0^QVP;[RN.*[EDV0Y%^\X@S&&98N&JRS+:JG[R^SBL<DZ5%
M7^*%'VM6VSBSSI9_Q+Q&O8\+95/)\#+26;YM1=.T?YL%ES:K5VU\%2O[*C?=
M21Z9X"\`Z?X"TZ\MX-1U?7=7UB\_M/Q%XDUZ\>]U?7=4,20&ZN6XBMH4ACCA
MAM;>..*&*-$5>"S>!G&<5LWKTIRH4<'AL+#V6&PN'@J='#TKN7)%?%*4I-RG
M4FY3G-N3>J2^FR+(</D.'K4Z>(KXW%XNI[;%XO%5'4KXFM91YY/X81C%*%.E
M3484X)12=FWW=>0>X%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`C*K*58!E8%65@"I4C!!!X((XQ0FTTT[-;":3335T]&GM8\WUGX.?"O7K
MA[S5OA_X4N+R4L9;Q-&L[2\E9V+.TMU9QQ2RN6))9G)Y//->[A>)^(<%!4L-
MG.+ITHVY8.O.<(V5DE";E%*W1)(^<QG!W"N/J2K8KA_`U*TK\U18>G3J2;=V
MY5*:A-MOJVV<X/V=/@WE-W@\RI&ZNL%QXA\57-KE3E5:TN-<>%XQV1HRN.,8
M%=W^N_%&MLSY&U;FCAL)">N]IQH*:?FFGYGF_P#$.N#=+Y/S*+349XO'3AIL
MG3EB7!I?RN+7D=IX=^&?P\\)2>=X:\$^%]%N=SN;NPT6PAO2T@`<F]$'GG<%
M&09*\K&Y]G>8QY,=FN+Q5.R7)4KU'3TV_=\W)U_E/:R[AGA[*)<^6Y)@L%4U
M?M*6&I1J:Z/]YR^TUMMS6.XKR3W`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
+"@`H`*`"@`H`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
